- Researchers have posted the results of a multisystem phase II clinical trial of patients with COVID-19 and respiratory failure
- Patients who received inhaled nitric oxide had improved blood oxygen levels and fewer risks of long-term sensory and motor neurologic symptoms
- They also experienced a faster reduction of viral load in sputum and blood
BOSTON – Inhaled nitric oxide gas widens blood vessels in the lungs and is used to treat severe cardio-pulmonary conditions in newborns and adults.
A recent multicenter international phase II clinical trial led by investigators at Massachusetts General Hospital (MGH) and the University of Alabama in Birmingham (UAB) has revealed that inhaled nitric oxide can benefit patients with respiratory failure due to COVID-19 pneumonia.
The investigator-initiated multi-center trial, which commenced recruitment in March 2020, stands as a testament to the collaborative spirit that prevailed even at the height of the pandemic. The findings are published in the American Journal of Respiratory and Critical Care Medicine.
Prior clinical trials have shown that low-dose (1–20 parts per million) inhaled nitric oxide boosts blood oxygen levels in critically ill patients with acute lung injury.
Low-dose inhaled nitric oxide also improved oxygenation during the severe acute respiratory syndrome (SARS) outbreak of 2003, and recent laboratory experiments showed that nitric oxide inhibits replication of SARS‑CoV‑2.
To test the potential of inhaled nitric oxide gas to treat SARS‑CoV‑2–infected patients who develop lung complications, investigators randomized 193 adults with COVID-19 and respiratory failure who were on ventilators at four hospitals in the United States and one in Sweden to receive high-dose (up to 80 parts per million) nitric oxide for 48 hours or to receive usual care.
Patients who received nitric oxide experienced improved oxygenation and had fewer risks of long-term sensory and motor neurologic symptoms (such as weakness or pain in the extremities) compared with patients receiving usual care.
They also had lower levels of SARS-CoV-2 in their blood and sputum, suggesting that nitric oxide has anti-viral activity. Inhaled nitric oxide was well tolerated and was not linked to any serious adverse events.
Despite these findings, the duration of ventilation and the rates of death at 28 and 90 days did not differ significantly between patients on nitric oxide and those receiving usual care.
"In addition to the well-documented effects on oxygenation, these findings suggest new and promising advantages of utilizing high-concentration inhaled nitric oxide as an antimicrobial agent," says co–senior author Lorenzo Berra, MD, who is the medical director of Respiratory Care at MGH and the Reginald Jenney Associate Professor of Anaesthesia at Harvard Medical School.
"These results highlight the importance of planning future dose-response investigations into the anti-microbial and clinical properties of high-dose inhaled nitric oxide therapy in adults with acute hypoxemic respiratory failure."
"The outcomes of this trial will serve as a critical reference for future research, shedding light on specific subgroups like Black and obese individuals, in whom high-dose inhaled nitric oxide may yield more substantial clinical benefits," said co-senior author Pankaj Arora, MD, director of the Cardiovascular Clinical and Translational Research Program and the Cardiovascular and Genetics Clinic Program at the UAB Marnix E. Heersink School of Medicine.
"This is especially relevant given the underlying suppression and relative deficiency of the nitric oxide-cGMP signaling system in these populations."
The investigator-initiated multi-center trial, which commenced recruitment in March 2020, stands as a testament to the collaborative spirit that prevailed even at the height of the pandemic.
Additional authors include Raffaele Di Fenza, MD; Naman S Shetty, MD; Stefano Gianni, MD; Vibhu Parcha, MD; Valentina Giammatteo, MD; Bijan Safaee Fakhr, MD; Daniel Tornberg, MD, PhD; Olof Wall, MD, PhD; Piotr Harbut, MD, PhD; Peggy S. Lai, MD; Jonathan Z. Li, MD; Sabrina Paganoni, MD PhD; Stefano Cenci, MD; Ariel L. Mueller, BA; Timothy T. Houle, PhD; Oluwaseun Akeju, MD; Edward A. Bittner, MD PhD; Somnath Bose, MD; Louie K Scott, MD; Ryan W Carroll, MD, MPH; Fumito Ichinose, MD, PhD; and Magnus Hedenstierna, MD.
Each institution provided funding for costs related to the trial.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. MGH is a founding member of the Mass General Brigham healthcare system.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in fullhere